Patents by Inventor Drazen Raucher

Drazen Raucher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of metastasis by cell penetrating peptides
    Patent number: 9682118
    Abstract: A compound including a cell penetrating peptide (CPP) and elastin-like polypeptide (ELP), and a method for use thereof, are useful for inhibiting the proliferation of cancer.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: June 20, 2017
    Assignee: University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III
  • Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
    Patent number: 9259432
    Abstract: Compositions for targeting to a desired region of the brain or spinal cord include a therapeutic compound useful for the treatment of a neurodegenerative disease; a cell penetrating peptide (CPP); and a thermal targeting polypeptide (TTP).
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 16, 2016
    Assignee: Parminder J. S. Vig
    Inventors: Parminder J. S. Vig, Drazen Raucher, Scoty Hearst
  • Targeted delivery of therapeutic peptides by thermally responsive biopolymers
    Patent number: 8841414
    Abstract: A compound including a cell penetrating peptide (CPP), an elastin-like polypeptide (ELP), and a therapeutic peptide (TP) can be preferentially directed to a target site by applying hyperthermia. The compound can be useful for the treatment of tumors.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 23, 2014
    Assignee: University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III
  • Thermally-targeted delivery of medicaments including doxorubicin
    Patent number: 8252740
    Abstract: Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat peptide, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) (SEQ ID NO: 3) spacer and a cysteine residue (SEQ ID NO: 4) conjugated to therapeutic such as doxorubicin, or an analog thereof.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: August 28, 2012
    Assignee: The University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III, Waldemar Priebe, Izabela Fokt
  • THERMALLY-TARGETED DELIVERY OF MEDICAMENTS INCLUDING DOXORUBICIN
    Publication number: 20100022466
    Abstract: Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat protein, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer and a cysteine residue conjugated to therapeutic such as doxorubicin, or a analog thereof.
    Type: Application
    Filed: January 29, 2007
    Publication date: January 28, 2010
    Inventors: Drazen Raucher, Gene Bidwell, III, Waldemar Priebe, Izabela Fokt